• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在轻度条件下,重新评估样本量导致增加样本量不会增加Ⅰ类错误率。

Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.

机构信息

Department of Oncology and Cancer Epidemiology, Clinical Sciences, Lund University and Skåne University Hospital, 221 85 Lund, Sweden.

出版信息

BMC Med Res Methodol. 2013 Jul 19;13:94. doi: 10.1186/1471-2288-13-94.

DOI:10.1186/1471-2288-13-94
PMID:23870495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3738874/
Abstract

BACKGROUND

One major concern with adaptive designs, such as the sample size adjustable designs, has been the fear of inflating the type I error rate. In (Stat Med 23:1023-1038, 2004) it is however proven that when observations follow a normal distribution and the interim result show promise, meaning that the conditional power exceeds 50%, type I error rate is protected. This bound and the distributional assumptions may seem to impose undesirable restrictions on the use of these designs. In (Stat Med 30:3267-3284, 2011) the possibility of going below 50% is explored and a region that permits an increased sample size without inflation is defined in terms of the conditional power at the interim.

METHODS

A criterion which is implicit in (Stat Med 30:3267-3284, 2011) is derived by elementary methods and expressed in terms of the test statistic at the interim to simplify practical use. Mathematical and computational details concerning this criterion are exhibited.

RESULTS

Under very general conditions the type I error rate is preserved under sample size adjustable schemes that permit a raise. The main result states that for normally distributed observations raising the sample size when the result looks promising, where the definition of promising depends on the amount of knowledge gathered so far, guarantees the protection of the type I error rate. Also, in the many situations where the test statistic approximately follows a normal law, the deviation from the main result remains negligible. This article provides details regarding the Weibull and binomial distributions and indicates how one may approach these distributions within the current setting.

CONCLUSIONS

There is thus reason to consider such designs more often, since they offer a means of adjusting an important design feature at little or no cost in terms of error rate.

摘要

背景

自适应设计(如样本量可调设计)的一个主要问题是担心会使Ⅰ型错误率膨胀。然而,在(Stat Med 23:1023-1038, 2004)中证明,当观测值服从正态分布且中期结果显示有希望时,即条件功效超过 50%,则可以保护Ⅰ型错误率。这个界限和分布假设似乎对这些设计的使用施加了不理想的限制。在(Stat Med 30:3267-3284, 2011)中,探索了低于 50%的可能性,并根据中期的条件功效定义了一个允许增加样本量而不膨胀的区域。

方法

通过基本方法推导出一个(Stat Med 30:3267-3284, 2011)中隐含的标准,并以中期的检验统计量表示,以简化实际使用。展示了关于该标准的数学和计算细节。

结果

在非常一般的条件下,允许增加样本量的样本量可调方案可以保持Ⅰ型错误率。主要结果表明,对于正态分布的观测值,当结果看起来有希望时(有希望的定义取决于迄今为止收集的知识量),增加样本量可以保证Ⅰ型错误率的保护。此外,在检验统计量近似服从正态规律的许多情况下,偏离主要结果仍然可以忽略不计。本文详细介绍了威布尔和二项式分布,并指出如何在当前的设置中接近这些分布。

结论

因此,有理由更多地考虑这种设计,因为它们提供了一种在不增加错误率的情况下调整重要设计特征的方法。

相似文献

1
Sample size re-assessment leading to a raised sample size does not inflate type I error rate under mild conditions.在轻度条件下,重新评估样本量导致增加样本量不会增加Ⅰ类错误率。
BMC Med Res Methodol. 2013 Jul 19;13:94. doi: 10.1186/1471-2288-13-94.
2
Increasing the sample size when the unblinded interim result is promising.当非盲法中期结果有希望时增加样本量。
Stat Med. 2004 Apr 15;23(7):1023-38. doi: 10.1002/sim.1688.
3
Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications.多臂临床试验中采用适应性中期样本量调整时的最大I型错误率膨胀。
Biom J. 2014 Jul;56(4):614-30. doi: 10.1002/bimj.201300153. Epub 2014 Apr 22.
4
Adaptive sample size modification in clinical trials: start small then ask for more?临床试验中的适应性样本量调整:从小规模开始然后再增加?
Stat Med. 2015 Dec 20;34(29):3793-810. doi: 10.1002/sim.6575. Epub 2015 Jul 14.
5
Operating characteristics of sample size re-estimation with futility stopping based on conditional power.基于条件把握度进行无效性终止的样本量重新估计的操作特征
Stat Med. 2006 Oct 15;25(19):3348-65. doi: 10.1002/sim.2455.
6
Multiplicity and flexibility in clinical trials.临床试验中的多样性与灵活性。
Pharm Stat. 2007 Jul-Sep;6(3):205-16. doi: 10.1002/pst.302.
7
Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.基于有前景的中期结果的样本量调整及其在确证性临床试验中的应用。
Clin Trials. 2015 Dec;12(6):584-95. doi: 10.1177/1740774515594378. Epub 2015 Jul 20.
8
Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.临床试验中灵活的样本量设计方法:似然比、加权、双检验和有希望区方法。
Contemp Clin Trials. 2016 Mar;47:40-8. doi: 10.1016/j.cct.2015.12.007. Epub 2015 Dec 7.
9
Precision of maximum likelihood estimation in adaptive designs.适应性设计中最大似然估计的精度。
Stat Med. 2016 Mar 15;35(6):922-41. doi: 10.1002/sim.6761. Epub 2015 Oct 12.
10
Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.当测试平均生物等效性时,控制两阶段序贯自适应设计中的 I 类错误率。
Stat Med. 2018 May 10;37(10):1587-1607. doi: 10.1002/sim.7614. Epub 2018 Feb 20.

引用本文的文献

1
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.维得利珠单抗预防异基因造血干细胞移植后肠道急性移植物抗宿主病:一项随机 3 期试验。
Nat Med. 2024 Aug;30(8):2277-2287. doi: 10.1038/s41591-024-03016-4. Epub 2024 Jun 6.
2
RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial.RNA 聚合酶抑制剂恩沙替尼治疗中度 COVID-19 患者的随机、安慰剂对照、多中心、双盲 3 期临床试验。
Adv Respir Med. 2024 May 6;92(3):202-217. doi: 10.3390/arm92030021.
3
EMAGINE-Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke.EMAGINE-一项随机对照试验的研究方案,旨在确定频率调谐电磁场治疗对促进缺血性中风亚急性期恢复的疗效。
Front Neurol. 2023 May 5;14:1148074. doi: 10.3389/fneur.2023.1148074. eCollection 2023.
4
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial.依尼沙米是一种严重急性呼吸综合征冠状病毒2(SARS-CoV-2)RNA聚合酶抑制剂,在一项临床试验的中期分析中显示可改善新冠病毒病(COVID-19)患者的康复情况。
medRxiv. 2021 Jan 21:2021.01.05.21249237. doi: 10.1101/2021.01.05.21249237.
5
A systematic review of the "promising zone" design.一种“有希望区域”设计的系统评价。
Trials. 2020 Dec 4;21(1):1000. doi: 10.1186/s13063-020-04931-w.
6
OARSI Clinical Trials Recommendations: Key analytic considerations in design, analysis, and reporting of randomized controlled trials in osteoarthritis.骨关节炎研究学会(OARSI)临床试验建议:骨关节炎随机对照试验设计、分析及报告中的关键分析考量因素
Osteoarthritis Cartilage. 2015 May;23(5):677-85. doi: 10.1016/j.joca.2015.03.011.

本文引用的文献

1
Adaptive increase in sample size when interim results are promising: a practical guide with examples.当中期结果有希望时自适应增加样本量:附实例的实用指南。
Stat Med. 2011 Dec 10;30(28):3267-84. doi: 10.1002/sim.4102. Epub 2010 Nov 30.
2
Maximum inflation of the type 1 error rate when sample size and allocation rate are adapted in a pre-planned interim look.当在预先计划的中期观察中调整样本量和分配率时,Ⅰ类错误率的最大膨胀。
Stat Med. 2011 Jun 30;30(14):1637-47. doi: 10.1002/sim.4230. Epub 2011 Apr 15.
3
A seamless phase II/III design with sample-size re-estimation.具有样本量重新估计的无缝II/III期设计。
J Biopharm Stat. 2009 Jul;19(4):595-609. doi: 10.1080/10543400902963193.
4
Sample size re-estimation for adaptive sequential design in clinical trials.临床试验中适应性序贯设计的样本量重新估计。
J Biopharm Stat. 2008;18(6):1184-96. doi: 10.1080/10543400802369053.
5
Improving interval estimation of binomial proportions.改进二项比例的区间估计。
Philos Trans A Math Phys Eng Sci. 2008 Jul 13;366(1874):2405-18. doi: 10.1098/rsta.2008.0037.
6
Are flexible designs sound?灵活的设计合理吗?
Biometrics. 2006 Sep;62(3):664-9; discussion 670-83. doi: 10.1111/j.1541-0420.2006.00626.x.
7
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.在中期进行假设选择的验证性无缝II/III期临床试验:一般概念
Biom J. 2006 Aug;48(4):623-34. doi: 10.1002/bimj.200510232.
8
Sample size recalculation in internal pilot study designs: a review.内部预试验研究设计中的样本量重新计算:综述
Biom J. 2006 Aug;48(4):537-55. doi: 10.1002/bimj.200510238.
9
A general statistical principle for changing a design any time during the course of a trial.在试验过程中的任何时候更改设计的一般统计原则。
Stat Med. 2004 Aug 30;23(16):2497-508. doi: 10.1002/sim.1852.
10
Increasing the sample size when the unblinded interim result is promising.当非盲法中期结果有希望时增加样本量。
Stat Med. 2004 Apr 15;23(7):1023-38. doi: 10.1002/sim.1688.